New drug trial offers hope for psoriatic arthritis patients
NCT ID NCT04314531
Summary
This Phase 3 study is testing whether the drug tildrakizumab helps control active psoriatic arthritis in people who haven't tried certain other arthritis medications. About 296 participants will receive either the actual drug or a placebo injection to compare effectiveness and safety. The main goal is to see if the drug reduces joint pain and swelling by at least 20% compared to starting levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sunpharma Site 100
Madrid, 28046, Spain
-
Sunpharma Site 106
Lucknow, Uttar Pradesh, 226003, India
-
Sunpharma Site 107
Belagavi, Karnataka, 590016, India
-
Sunpharma Site 108
Pune, Maharashtra, 411004, India
-
Sunpharma Site 109
Hubli, Karnataka, 580021, India
-
Sunpharma Site 110
Bangalore, Karnataka, 560079, India
-
Sunpharma Site 111
Surat, Gujarat, 395010, India
-
Sunpharma Site 112
Hyderabad, Telangana, 500003, India
-
Sunpharma Site 113
Kochi, 682040, India
-
Sunpharma Site 18
Incheon, 22332, South Korea
-
Sunpharma Site 19
Seoul, 4763, South Korea
-
Sunpharma Site 20
Seoul, 3080, South Korea
-
Sunpharma Site 22
Kitakyushu-shi, 802-8561, Japan
-
Sunpharma Site 23
Tsu, 514-8507, Japan
-
Sunpharma Site 24
Miyazaki, Miyazaki, 889-1692, Japan
-
Sunpharma Site 39
Phillip, Australian Capital Territory, 2606, Australia
-
Sunpharma Site 63
Zlín, 760 01, Czechia
-
Sunpharma Site 64
Brno, 638 00, Czechia
-
Sunpharma Site 71
Córdoba, 14004, Spain
-
Sunpharma Site 72
Seville, 41013, Spain
-
Sunpharma Site 73
Berlin, 12161, Germany
-
Sunpharma Site 74
Poznan, 61-113, Poland
-
Sunpharma Site 75
A Coruña, 15006, Spain
-
Sunpharma Site 84
Nagoya, Aichi-ken, 467-0001, Japan
-
Sunpharma Site 85
Shinjuku, Tokyo, 160-0023, Japan
-
Sunpharma Site 86
Sendai, Miyagi, 980-8574, Japan
-
Sunpharma Site 87
Osaka, 545-0051, Japan
-
Sunpharma Site 88
Kumamoto, 860-8556, Japan
-
Sunpharma Site 89
Kitakyushu, Fukuoka, 802-8561, Japan
-
Sunpharma Site 90
tabashi City, Tokyo, 173-8606, Japan
-
Sunpharma Site 91
Mitaka, Tokyo, 181-8611, Japan
-
Sunpharma Site 92
Herne, 44649, Germany
-
Sunpharma Site 93
Bialystok, 15-351, Poland
-
Sunpharma Site 94
Lublin, 20-607, Poland
-
Sunpharma Site 95
Bialystok, 15-879, Poland
-
Sunpharma Site 96
Warsaw, 02-118, Poland
-
Sunpharma Site 97
Prague, 12800, Czechia
-
Sunpharma site no. 01
Tomball, Texas, 77375, United States
-
Sunpharma site no. 02
New Port Richey, Florida, 34652, United States
-
Sunpharma site no. 03
San Antonio, Texas, 78229, United States
-
Sunpharma site no. 04
Miami Beach, Florida, 33140, United States
-
Sunpharma site no. 05
Springfield, Missouri, 65810, United States
-
Sunpharma site no. 06
Spokane, Washington, 99204, United States
-
Sunpharma site no. 07
Tamarac, Florida, 33321, United States
-
Sunpharma site no. 08
Hobart, Tasmania, 7000, Australia
-
Sunpharma site no. 09
Lubbock, Texas, 79410, United States
-
Sunpharma site no. 10
Lincoln, Nebraska, 68516, United States
-
Sunpharma site no. 11
Greenville, South Carolina, 29601, United States
-
Sunpharma site no. 12
Covina, California, 91722, United States
Conditions
Explore the condition pages connected to this study.